KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Finished Goods: 2010-2020

Historic Finished Goods for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Dec 2020 value amounting to $313.6 million.

  • Biomarin Pharmaceutical's Finished Goods fell 20.79% to $261.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $261.6 million, marking a year-over-year decrease of 20.79%. This contributed to the annual value of $313.6 million for FY2020, which is 22.57% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Finished Goods of $313.6 million as of FY2020, which was up 22.57% from $255.9 million recorded in FY2019.
  • Biomarin Pharmaceutical's Finished Goods' 5-year high stood at $313.6 million during FY2020, with a 5-year trough of $136.1 million in FY2016.
  • In the last 3 years, Biomarin Pharmaceutical's Finished Goods had a median value of $255.9 million in 2019 and averaged $264.9 million.
  • Data for Biomarin Pharmaceutical's Finished Goods shows a peak YoY skyrocketed of 80.78% (in 2016) over the last 5 years.
  • Biomarin Pharmaceutical's Finished Goods (Yearly) stood at $136.1 million in 2016, then surged by 40.51% to $191.2 million in 2017, then climbed by 17.76% to $225.2 million in 2018, then grew by 13.62% to $255.9 million in 2019, then climbed by 22.57% to $313.6 million in 2020.